Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (5555)	9/15/1998 9:38:00 PM
From: Brander	Read Replies (1) \| Respond to of 9523

Here is a nice Viagra success story: 65 YO business exec who is S/P CVA approximately 5 years ago, leaving him impotent. "I haven't been able to do a thing for 5 years." After appropriate medical W/U, he was started on Viagra 50mg. At his next appointment, he reported a very good response. "It is like I'm 30 again." He reported no side effects. I continue to be impressed with the effectiveness and side effect profile of Viagra, when used according to label. Brad

To: flickerful who wrote (5555)	9/16/1998 8:39:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

09/16 04:47 Pfizer Belgium sees Viagra price in line across EU BRUSSELS, Sept 16 (Reuters) - The Belgian unit of U.S. drugs group Pfizer Inc <PFE.N> on Wednesday said it expects the price of its blockbuster anti-impotency drug Viagra in Belgium to be in line with the drug's price throughout the European Union. "The goal is to arrive at similar pricing throughout all the member countries of the European Union," Nicolas Van Houcke, media manager for Pfizer Belgium, told Reuters. In France Viagra is to be priced at 60 francs (about $10) a pill. In the UK, the price has been set at 4.84 pounds per pill ($8.09). Pfizer Belgium plans to submit its pricing request for Viagra to the economics affairs ministry within the next few days, he said. The ministry would then have up to 90 days to review the request, making December 20 the deadline under Pfizer's submission plans. "It is possible the ministry could act more quickly," Van Houcke said. Pfizer will not initially seek government permission for social security reimbursement coverage on Viagra. "We will launch it without reimbursement," Van Houcke said. Not seeking reimbursement will speed the drug's introduction and will help avoid the possibility of having French citizens coming to Belgium for the drug, he said. France, Germany, Italy and Denmark have all already said that they will not offer government reimbursement for the drug. Britain earlier this week said it had banned doctors from prescribing the drug to National Health Service patients. Van Houcke declined to provide a sales forecast for Viagra in Belgium. One U.S. market research firm, IMS Health, has estimated that Viagra sales will hit $1 billion in its debut year on the market, although only a minority of U.S. users are being reimbursed by insurers. The blue, diamond-shaped pills were introduced initially to the U.S. market in April, instantly becoming the most successful new drug launch ever. Viagra has also been the most successful drug launch in Switzerland, where it was approved for sale in June.